Darrel E. Drachenberg¹, David G. Bell²

Canadian Journal of Urology, Vol.9, No.4, pp. 1602-1606, 2002

Abstract Background: The treatment of localized prostate cancer has increased over the past decade in large part due to enhanced screening efforts with prostate specific antigen (PSA) and has resulted in a dramatic increase in the number of radical retropubic prostatectomies being performed in recent years. It is estimated that between 5% and 10% of men who are candidates for radical surgical treatment for localized prostate cancer will have concomitant inguinal hernia. Given the well described complications of untreated inguinal hernias we propose that simultaneous repair be undertaken along with radical retropubic prostatectomy for preoperatively defined hernias More >

Marc David¹, Luis Souhami¹, Armen Aprikian²

Canadian Journal of Urology, Vol.9, No.4, pp. 1599-1601, 2002

Abstract A case of post renal acute renal failure secondary to radiation therapy for prostate cancer is described. Severe bladder inflammatory reaction, leading to bilateral ureteric obstruction, occurred after a moderate dose of radiotherapy (6400 cGy in 35 fractions). At a follow-up time of 8 years, the patient has fully recovered and remains disease-free. To our knowledge, this complication has never been described previously. Given the thrust in prostate cancer treatment toward dose escalation this complication could become more frequent. More >

Fred Saad, Robert Sabbagh, Michael McCormack, François Peloquin

Canadian Journal of Urology, Vol.9, No.4, pp. 1592-1594, 2002

Abstract Purpose: To compare patient reported pain during TRUS guided biopsies using intrarectal lidocaine gel versus lubricating gel.
Materials and methods: From May 2000 to May 2001, 360 men undergoing transrectal prostate biopsy were enrolled in this study. Patients were randomized into two groups. In group 1, 180 patients received 10 cc of 2% intrarectal lidocaine gel (Xylocaine® 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure and in group 2, 180 patients received 10 cc of lubricating gel. No other sedation or analgesia was given. Pain level immediately after the last biopsy was assessed More >

Tom Pickles¹, Andy Coldman², Norm Phillips³

Canadian Journal of Urology, Vol.9, No.3, pp. 1551-1557, 2002

Abstract Objective: To evaluate changes of prostate cancer incidence, referrals, stage, treatment and outcomes delivered in British Columbia since the 1980's.
Materials and methods: Examination of the BC Provincial Tumour Registry, BC Cancer Agency (BCCA) and BC Medical Services Plan databases.
Results: The number of incident cases increased linearly from 1980 through 1990. Between 1991 and 1995 a harvesting effect was seen due to unofficial PSA screening, balanced by a post-harvest effect between 1995 and 1998. Since 1999 the incidence has resumed the linear trend extrapolated from the 1980's. The age-standardised incidence rate has recently risen in younger (<65yrs)… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, No.3, pp. 1544-1550, 2002

Abstract Superficial bladder tumors are by far the most common form of bladder cancer managed by practicing urologists. Indeed up to 75% of initial tumors fall in this category and because of the high recurrence rate, superficial tumors represent over 90% of tumor events being treated. New diagnostic methods have been developed to improve the sensitivity of tumor detection of both cystoscopy and urinary cytology. Risk stratification of patients based on simple clinical parameters provides new opportunities for adapting monitoring strategies as well as providing a rationale for the use of intravesical chemotherapy and immunotherapy. Finally, More >

Ö. L. Özdal¹, Y. K. Yakupoglu¹, A. Çiçek¹, Ö. Erdem², L. Memis², A. Memis¹

Canadian Journal of Urology, Vol.9, No.2, pp. 1498-1499, 2002

Abstract We report a 55 year old man complaining of painless left testicular swelling that developed over 2 months. The imaging studies revealed an epididymal mass separate from the testicle. The patient underwent left radical orchiectomy. The histopathological examination of the orchiectomy specimen revealed poorly differentiated signet cell metastatic adenocarcinoma. More >

Iain McAuley¹, Gary Steinhoff¹, Michael McNeely², Paul Blood³

Canadian Journal of Urology, Vol.9, No.2, pp. 1496-1497, 2002

Abstract A man with a prostate specific antigen (PSA) of 6.1 ng/mL, a clinical stage T2b prostate nodule and biopsies that showed Gleason sum 6 adenocarcinoma of the prostate underwent a radical prostatectomy. The final pathology showed organ-confined disease. His postoperative PSA remained elevated at 4.0 ng/mL. The PSA was repeated several times and was in the same range. It was re-evaluated at another lab facility and was unmeasurable ( <0.02 ng/mL). He has an antibody that cross-reacts with an assay reagent causing this false reading. The most likely antibody is one against mouse immunoglobulin G More >

Dr. Richard Choo

Canadian Journal of Urology, Vol.9, No.1, pp. 1453-1453, 2002

Abstract This article has no abstract. More >

Charles Catton¹, Mary Gospodarowicz¹, Jimmy Mui¹, Tony Panzarella², Michael Milosevic¹, Michael McLean¹, Pamela Catton¹, Padraig Warde¹

Canadian Journal of Urology, Vol.9, No.1, pp. 1444-1452, 2002

Abstract Purpose: To retrospectively review the results of conventional dose radical radiotherapy for clinical stage T1 and T2 prostate cancer, and to identify the factors that predict the biochemical relapse-free rate.
Methods: The records were reviewed of 706 hormonally-naive men with clinical stage T1T2 prostate cancer treated with radical radiotherapy (RT) between 1987-1994 at the Princess Margaret Hospital. The median prostate RT dose was 65 Gy in 35 fractions (range 52 Gy in 20 fractions to 67 Gy in 37 fractions). Pelvic lymph nodes were included in the treatment volume and treated to a median dose of 45… More >

M.A. MONTENEGRO^*, M. SÁNCHEZ NEGRETTE^*, E.J. GIMENO^**, J.T. BORDA^*

BIOCELL, Vol.26, No.3, pp. 339-345, 2002, DOI:10.32604/biocell.2002.26.339

Abstract Wistar male rats, 3 months of age were given ad-libitum a nutritionally adequate diet and demineralized drinking water. The Molybdenum (Mo) and Tungsten (W) were provided in the drinking water at 200 ppm concentration. Intestinal tumors were induced by 1,2-dimethylhydrazine (DMH) given subcutaneously as 16 weekly doses at 20 mg/kg body weight. Mo in the form of (NH₄)₆ Mo₇O₂₄ 4H₂O or W in the form of (Na₂ WO₄) were provided in the drinking water two months before the first DMH treatment and were continued during 4 months more until the last DMH treatment. Three months after the last… More >